SCUBE3-Related Short Stature Syndrome (SSFSC2): Comprehensive Disease Characterization

Disease: SCUBE3-Related Short Stature Syndrome Formal name: Short stature, facial dysmorphism, and skeletal anomalies with or without cardiac anomalies 2 (SSFSC2) MONDO: MONDO:0030953 · OMIM: 619184 · Category: Mendelian (autosomal recessive) Date compiled: 2026-09-05

Summary

SCUBE3-Related Short Stature Syndrome (SSFSC2) is an ultra-rare, autosomal-recessive Mendelian disorder caused by biallelic loss-of-function variants in SCUBE3 (Signal peptide-CUB-EGF domain-containing protein 3; HGNC:23310, NCBIGene:222663, chromosome 6p21.31, UniProt Q8IX30). The disorder was first defined as a discrete clinical entity by Lin and colleagues in 2021, who described 18 affected individuals from 9 unrelated families sharing a consistent phenotype of reduced growth, skeletal features, a distinctive craniofacial appearance, and dental anomalies (PMID: 33308444). As of 2025, approximately 20 patients from around 10 families have been reported worldwide (PMID: 40331102).

Mechanistically, SCUBE3 is a secreted/cell-surface-anchored glycoprotein that functions as a co-receptor for bone morphogenetic proteins BMP2/BMP4, recruiting BMP receptor complexes into lipid-raft microdomains and augmenting BMP–BMP type I receptor interactions. It also modulates TGF-β (via SMAD2/3), FGF, and Hedgehog signaling. Biallelic loss-of-function impairs transcript processing, protein secretion, and co-receptor function, dysregulating BMP signaling. Because BMP-mediated chondrogenesis and osteogenesis are essential for endochondral bone formation at the growth plate, SCUBE3 deficiency produces prenatal-onset short stature and skeletal/craniofacial/dental abnormalities. The Scube3⁻/⁻ knockout mouse faithfully recapitulates the human disorder, exhibiting craniofacial and dental defects, reduced body size, and defective endochondral bone growth due to impaired BMP-mediated chondrogenesis and osteogenesis (PMID: 33308444).

Clinically, the syndrome is non-lethal with generally normal cognition and normal life expectancy. Diagnosis is molecular—recognition of the clinical gestalt followed by exome/genome sequencing or a short-stature/skeletal-dysplasia gene panel. There is no disease-modifying therapy; management is supportive and multidisciplinary (orthopedic/spinal, dental/orthodontic, cardiac surveillance, growth monitoring). The GH/IGF-1 axis is typically normal, so the growth failure reflects a local growth-plate BMP-signaling defect rather than classic growth-hormone deficiency.

Section 1 — Disease Information

Overview. SSFSC2 is a syndromic short-stature disorder of prenatal onset combining growth retardation, a recognizable craniofacial gestalt (long/triangular face, high forehead, long nose, small pointed chin), skeletal anomalies (brachydactyly, short long bones, scoliosis, 11 rib pairs), and dental anomalies (crowding, enamel defects), typically with preserved cognition (PMID: 33308444).

Key identifiers.

Synonyms / alternative names: Short stature, facial dysmorphism, and skeletal anomalies with or without cardiac anomalies 2 (SSFSC2); SCUBE3-related short stature syndrome; SCUBE3-related developmental disorder; SCUBE3 deficiency. Gene aliases: SCUBE3, CEGF3.

Data source type: Information is derived from aggregated disease-level resources (OMIM, MONDO, HPO annotations) built on individual-patient case series from the primary literature; there is no large EHR-derived dataset for this ultra-rare condition. No dedicated Orphanet ORPHA code or MeSH term has been identified; MONDO:0030953 / OMIM:619184 are the canonical entries.

Section 2 — Etiology

Primary cause: Purely genetic—biallelic (homozygous or compound heterozygous) loss-of-function variants in SCUBE3. There is no environmental, infectious, or multifactorial component; this is a monogenic germline disorder (PMID: 33308444).

"bi-allelic inactivating variants in SCUBE3 have pleiotropic consequences on development and cause a previously unrecognized syndromic disorder. Eighteen affected individuals from nine unrelated families showed a consistent phenotype characterized by reduced growth, skeletal features, distinctive craniofacial appearance, and dental anomalies." — PMID: 33308444

Genetic risk factors: The causal variants are inactivating SCUBE3 alleles (nonsense, canonical splice-site, exon-skipping deletions, and functionally validated missense variants). Consanguinity is a major driver, with homozygous variants reported in Turkish, Iranian, Saudi/Emirati, Indian, Israeli, and Brazilian families. No modifier genes have been established.

Environmental risk factors / protective factors / gene-environment interactions: None known or applicable. No lifestyle, occupational, toxic, or dietary factors have been implicated, and no protective alleles or environmental protective factors are reported.

Section 3 — Phenotypes

Phenotype frequencies below are drawn from HPO disease annotations for OMIM:619184, sourced from the founding cohort (~15 evaluable individuals; PMID: 33308444). The phenotype is prenatal-onset, non-progressive in its core growth deficit, and of variable expressivity.

"Eighteen affected individuals from nine unrelated families showed a consistent phenotype characterized by reduced growth, skeletal features, distinctive craniofacial appearance, and dental anomalies." — Lin et al. 2021

Key clinical points: - Cognition is usually normal (developmental delay/intellectual disability each ~7%), an important distinguishing feature. - Cardiac anomalies are variable (ASD, arrhythmia, patent foramen ovale)—hence "with or without cardiac anomalies" in the disease name. - Occasional/rare features: joint hypermobility or stiffness, nystagmus/strabismus/astigmatism, hypotonia, cleft palate, hypospadias, tracheobronchomalacia, bicoronal craniosynostosis, oropharyngeal dysphagia. The expanded ocular/skeletal spectrum (high-arched eyebrows, epicanthus, blepharoptosis, hypotelorism, radial bowing, irregular vertebral endplates, narrow iliac wings) was added by PMID: 40331102.

Severity/progression: Short stature is congenital and stable rather than progressive; scoliosis may progress and requires surveillance. Quality-of-life impact derives chiefly from short stature, skeletal (spinal) issues, and dental problems; disease-specific QoL instrument data (EQ-5D/SF-36/PROMIS) are not available.

Section 4 — Genetic / Molecular Information

Causal gene: SCUBE3 (HGNC:23310, NCBIGene:222663, 6p21.31, transcript NM_152753.4).

Pathogenic variant spectrum. ClinVar (accessed 2026) lists ~13 Pathogenic + 1 Pathogenic/Likely-pathogenic + 1 Likely-pathogenic SCUBE3 records among ~184 total (63 VUS, 4 benign/LB). Disease-associated variants converge on loss of function:

Contiguous-gene 6p21 CNV deletions (e.g., chr6:34.4–38.4 Mb) have also been reported (with severe IUGR). All variants are germline.

Functional consequences. In vitro validation showed variants variably impair transcript processing, protein secretion, and function, dysregulating BMP signaling:

"In vitro functional validation studies demonstrated a variable impact of disease-causing variants on transcript processing, protein secretion and function, and their dysregulating effect on bone morphogenetic protein (BMP) signaling." — PMID: 33308444

Population constraint (gnomAD, ENSG00000146197): pLI = 1.0; LOEUF (oe_lof_upper) = 0.378; oe_lof = 0.283 (33 observed vs 117 expected LoF); missense Z = 3.72. The gene is strongly constrained yet tolerant of heterozygous LoF alleles at low frequency—consistent with rare recessive carriers. No founder mutation established.

Modifier genes / epigenetics: No modifier genes or disease-specific epigenetic mechanisms have been reported. Chromosomal abnormalities: the contiguous-gene 6p21 microdeletions noted above.

Section 5 — Environmental Information

Not applicable. SSFSC2 is a monogenic germline disorder with no known environmental, lifestyle, or infectious contributors. No toxins, radiation, occupational exposures, dietary factors, or pathogens are implicated.

Section 6 — Mechanism / Pathophysiology

Ordered causal chain

1. Biallelic loss-of-function SCUBE3 variants (nonsense, splice, exon-skip, or destabilizing missense) → reduced/absent functional SCUBE3 protein, either through nonsense-mediated decay, impaired transcript processing, or defective secretion of misfolded protein. (Demonstrated in vitro; PMID: 33308444.)
2. Destabilizing missense variants (e.g., p.Cys303Ser) → disruption of a critical disulfide bridge in the 7th EGF-like repeat, impairing protein stability and reducing secretion. (AlphaFold3 modeling; PMID: 40331102.)
3. Loss of cell-surface SCUBE3 co-receptor → failure to recruit BMP receptor complexes into lipid-raft microdomains and reduced augmentation of BMP–BMP type I receptor interactions → decreased BMP2/BMP4 signaling. (Demonstrated; PMID: 33308444.)
4. Reduced BMP signaling (and altered TGF-β/SMAD2-3 co-modulation) → impaired SMAD-mediated transcriptional output in growth-plate cells. (BMP branch demonstrated; TGF-β branch inferred from CUB-domain ligand activity, PMID: 21441952.)
5. Impaired chondrogenesis and osteogenesis at the endochondral growth plate → defective endochondral bone growth. (Demonstrated in Scube3⁻/⁻ mouse; PMID: 33308444.)
6. Branch A: growth-plate defect → prenatal-onset short stature, short long bones, brachydactyly, scoliosis, rib anomalies. Branch B: cranial neural-crest/dental mesenchyme BMP defect → distinctive craniofacial gestalt and dental anomalies. Branch C (variable): cardiac BMP signaling perturbation → septal defects / arrhythmia in a minority.

Detail

Molecular pathways. The core lesion is in the BMP2/BMP4 signaling pathway (SMAD1/5/8 branch), with SCUBE3 acting as a positive co-receptor:

"We show that SCUBE3 acts as a BMP2/BMP4 co-receptor, recruits the BMP receptor complexes into raft microdomains, and positively modulates signaling possibly by augmenting the specific interactions between BMPs and BMP type I receptors." — PMID: 33308444

SCUBE3 additionally acts as an endogenous TGF-β type II receptor ligand through its C-terminal CUB domain, inducing SMAD2/3 phosphorylation:

"bound to transforming growth factor-β (TGF-β) type II receptor through the C-terminal CUB domain, activated TGF-β signaling and triggered the epithelial-mesenchymal transition (EMT). This process includes the induction of Smad2/3 phosphorylation" — PMID: 21441952

Recombinant SCUBE3 boosts BMP2/TGF-β expression and drives osteogenic differentiation via SMAD phosphorylation in human bone-marrow mesenchymal stem cells, reinforcing its pro-osteogenic role (PMID: 39250278). SCUBE family members also participate in FGF (zebrafish muscle development) and Hedgehog signaling.

Protein dysfunction. SCUBE3 (~993 aa) has five modular domains:

"organized into five modular domains: (1) an N-terminal signal peptide sequence, (2) nine tandem epidermal growth factor (EGF)-like repeats, (3) a large spacer region, (4) three cysteine-rich (CR) motifs, and (5) a CUB domain at the C-terminus" — PMID: 37237303

The cysteine-rich, disulfide-stabilized EGF-like repeats are essential for folding and secretion; pathogenic missense variants that eliminate cysteines (Cys97Trp, Cys303Ser, Cys519Ter) destabilize the protein and reduce secretion. Structural modeling confirms this:

"Protein modeling using AlphaFold3 revealed disruption of a critical disulfide bridge within the seventh epidermal growth factor-like repeat, likely affecting protein stability." — PMID: 40331102

Cellular processes and cell types. Upstream: chondrocytes and osteoblasts of the endochondral growth plate; cranial neural-crest-derived mesenchyme; odontoblasts/dental mesenchyme. Downstream clinical manifestations follow from impaired proliferation/differentiation in these lineages. Suggested GO terms: BMP signaling pathway (GO:0030509), chondrocyte differentiation (GO:0002062), osteoblast differentiation (GO:0001649), endochondral ossification (GO:0001958), SMAD protein signal transduction (GO:0060395). Suggested CL terms: chondrocyte (CL:0000138), osteoblast (CL:0000062), odontoblast (CL:0000060), neural crest cell (CL:0000333).

Metabolic / immune / epigenetic involvement. No primary metabolic derangement, immune dysregulation, or epigenetic mechanism is part of the core disease; the single interesting metabolic observation is that recombinant SCUBE3 activates mitophagy and ameliorates oxidative stress during osteogenesis in vitro (PMID: 39250278), which is peripheral to the germline disease.

Section 7 — Anatomical Structures Affected

Organ / system level (primary): Skeletal system—long bones, vertebral column, ribs, hands (brachydactyly), skull/craniofacial skeleton. Endocrine-independent growth failure (GH/IGF-1 axis normal). Secondary/variable: cardiovascular system (atrial septal defect, PFO, arrhythmia); dentition; occasionally airway (tracheobronchomalacia), palate, and eyes.

Suggested UBERON terms: skeletal system (UBERON:0001434), endochondral bone (UBERON:0002513), epiphyseal growth plate (UBERON:0002332), long bone (UBERON:0002495), vertebral column (UBERON:0001130), rib (UBERON:0002228), skull (UBERON:0003129), tooth (UBERON:0001091), heart (UBERON:0000948), interatrial septum (UBERON:0002085).

Tissue / cell level: Connective tissue—cartilage (growth-plate chondrocytes) and bone (osteoblasts); dental mesenchyme/odontoblasts; cranial neural crest derivatives. CL terms as above.

Subcellular level: Secreted/cell-surface (plasma-membrane-associated) glycoprotein; biosynthetic defects implicate the endoplasmic reticulum (folding/secretion, GO:0005783) and extracellular space / lipid-raft plasma-membrane microdomains (GO:0045121) where SCUBE3 co-receptor function occurs.

Localization / lateralization: Skeletal and craniofacial involvement is bilateral and largely symmetric; scoliosis introduces axial asymmetry; cardiac defects are structural (septal).

Expression sites: primary osteoblasts, long bones, axial-skeleton cartilage, vascular endothelium, platelets, and mammary ductal epithelium (PMID: 37237303, PMID: 40331102).

Section 8 — Temporal Development

• Onset: Congenital / prenatal. Intrauterine growth retardation and antenatal onset are documented in the majority (8/11 each). Short stature is present from birth.
• Onset pattern: Chronic/insidious—a developmental, non-inflammatory process.
• Progression: The core growth deficit is stable (non-progressive) rather than degenerative; the child remains short-statured. Scoliosis may progress through childhood/adolescence and requires monitoring.
• Disease course: Lifelong, chronic, non-episodic, non-relapsing.
• Critical periods: The prenatal and childhood growth-plate windows are the period of vulnerability; there is no known therapeutic window that reverses the growth-plate signaling defect.
• Remission: None (genetic, structural condition).

Section 9 — Inheritance and Population

• Inheritance: Autosomal recessive (HP:0000007), fully penetrant in reported biallelic cases with variable expressivity (PMID: 33308444, PMID: 40331102). Most cases are homozygous; some are compound heterozygous.
• Epidemiology: Ultra-rare. ~20 patients from ~10 families reported worldwide as of 2025; no prevalence or incidence estimate exists.

"is a very rare genetic disorder caused by biallelic pathogenic variants in the SCUBE3 gene and has been reported in approximately 20 patients to date" — PMID: 40331102

• Consanguinity: A major driver—homozygous variants in Turkish, Iranian, Saudi/Emirati, Indian, Israeli, and Brazilian families.
• Carrier frequency: Rare; gnomAD shows only 33 heterozygous LoF alleles (LOEUF 0.38). No founder mutation.
• Penetrance / anticipation / mosaicism: Complete penetrance for biallelic genotypes; no genetic anticipation (not a repeat-expansion disorder); no germline mosaicism reported.
• Sex ratio: No sex bias; both sexes affected.
• Population demographics: No population-specific prevalence beyond enrichment in consanguineous populations; no established geographic clustering of specific variants.

Section 10 — Diagnostics

Diagnostic approach — molecular. Recognition of the clinical gestalt (prenatal-onset short stature + long/triangular face, high forehead, long nose, small pointed chin + brachydactyly + dental crowding/enamel defects with preserved cognition) followed by confirmation of biallelic SCUBE3 variants: - Whole-exome sequencing (WES) — the original discovery method; high yield (PMID: 33308444). - Whole-genome sequencing (WGS) — captures splice/structural variants. - Multigene short-stature / skeletal-dysplasia panels including SCUBE3; SCUBE3 now appears on SGA/short-stature panels (PMID: 41001785). - Single-gene testing once the phenotype is recognized. - Chromosomal microarray (CMA) — detects contiguous-gene 6p21 deletions.

Supportive workup: skeletal survey/radiographs (brachydactyly, short long bones, scoliosis, 11 rib pairs, narrow iliac wings, vertebral endplate irregularities); echocardiography (ASD/PFO); dental/orthodontic evaluation; ophthalmologic exam; hearing assessment. Endocrine (GH/IGF-1) axis is typically normal—this is not classic GH deficiency, and there is no specific biomarker.

Differential diagnosis: 3M syndrome, Silver-Russell syndrome, Floating-Harbor syndrome, other primordial/skeletal-dysplasia short-stature disorders, ACAN- and COL2A1-related short stature. Preserved cognition, the specific facial gestalt, and biallelic SCUBE3 findings distinguish SSFSC2.

Screening: Carrier/cascade testing in affected consanguineous families; prenatal/preimplantation genetic testing where the familial variants are known. No population newborn screening exists (ultra-rare).

Section 11 — Outcome / Prognosis

• Survival / mortality: Non-lethal; life expectancy is generally normal. No disease-specific mortality data reported.
• Morbidity / function: Principal morbidity is short stature, skeletal (scoliosis) and dental problems; cognition is generally preserved, so functional/educational outcomes are usually good.
• Quality of life: Impacted mainly by stature, orthopedic, and dental issues; no formal QoL instrument data available.
• Complications: Scoliosis progression, dental crowding/enamel defects requiring orthodontic care, occasional cardiac defects requiring follow-up, rare airway issues (tracheobronchomalacia).
• Prognostic factors: Severity is variable and not strongly predicted by a single factor; no validated prognostic biomarkers exist.

Section 12 — Treatment

No disease-modifying or targeted therapy exists. Management is supportive, multidisciplinary, and symptom-directed:

Important caveat: Because the growth failure reflects a local growth-plate BMP-signaling defect rather than GH deficiency, recombinant human growth hormone is of unproven benefit. No pharmacogenomic, gene-therapy, cell-therapy, RNA-based, immunotherapy, or clinical-trial (NCT) interventions are currently available for this indication.

Section 13 — Prevention

Primary prevention of the disease itself is not possible (germline monogenic). Relevant preventive/genetic measures: - Genetic counseling for at-risk consanguineous families (25% recurrence risk per pregnancy for carrier couples). - Carrier / cascade screening of relatives once familial variants are identified. - Prenatal diagnosis / preimplantation genetic testing for known familial variants. - Tertiary prevention (preventing complications): scoliosis surveillance, dental prophylaxis/orthodontics, cardiac follow-up. No immunization, behavioral, environmental, or public-health interventions are applicable.

Section 14 — Other Species / Natural Disease

• Taxonomy / orthologs: Highly conserved across vertebrates (PMID: 37237303). Mouse Scube3 (NCBIGene:268935, chr17), rat Scube3 (NCBIGene:294297), zebrafish scube3 (NCBIGene:100000687).
• Natural disease: No naturally occurring SCUBE3 disease reported in companion animals or wildlife (no OMIA entry). No breed-specific (VBO) associations.
• Comparative biology: Disease mechanism (BMP co-receptor function in skeletal development) is evolutionarily conserved, enabling faithful mouse and zebrafish modeling.
• Transmission: Not applicable—no zoonotic or infectious component.

Section 15 — Model Organisms

Model characteristics:

"Scube3⁻/⁻ mice showed craniofacial and dental defects, reduced body size, and defective endochondral bone growth due to impaired BMP-mediated chondrogenesis and osteogenesis, recapitulating the human disorder." — PMID: 33308444

"Scube3N294K/N294K mutants showed morphological abnormalities of the skeleton, alterations of parameters relevant for bone metabolism, changes in renal function, and hearing impairments." — PMID: 27815347

Applications: growth-plate BMP signaling, skeletal/craniofacial/dental development, bone metabolism. Limitations: the knockout captures core skeletal/craniofacial phenotypes but human variant-specific hypomorphic effects (variable secretion/function) and the human cognitive-sparing may not be fully modeled by null alleles.

Mechanistic Model / Interpretation

Biallelic LoF SCUBE3 variants
  (nonsense / splice / exon-skip / destabilizing missense)
        │  NMD, impaired processing, misfolding (disulfide loss in EGF repeats)
        ▼
Reduced / non-functional secreted SCUBE3 co-receptor
        │  fails to recruit BMP receptor complexes to lipid rafts;
        │  loss of BMP–BMPR-I interaction augmentation
        ▼
Decreased BMP2/BMP4 signaling  ── (co-modulation) ── TGF-β/SMAD2/3, FGF, Hedgehog
        │  reduced SMAD1/5/8 transcriptional output
        ▼
Impaired chondrogenesis + osteogenesis at the endochondral growth plate
        │
        ├──► Branch A (skeleton): prenatal short stature, short long bones,
        │                         brachydactyly, scoliosis, 11 rib pairs
        ├──► Branch B (craniofacial/dental): long triangular face, high forehead,
        │                         long nose, pointed chin, dental crowding/enamel defects
        └──► Branch C (variable): cardiac septal defects / arrhythmia

Upstream vs downstream: the mutation → protein loss → BMP co-receptor failure steps are upstream and directly demonstrated in vitro and in the mouse; the tissue-specific clinical branches are downstream and reflect the developmental requirement for BMP signaling in each lineage. The consistency between the in-vitro co-receptor data, the AlphaFold3 structural modeling, and the faithful Scube3⁻/⁻ mouse gives this causal chain strong internal coherence.

Evidence Base

All primary mechanistic and clinical claims here are human clinical (cohort/case reports) reinforced by model-organism (mouse, zebrafish) and in-vitro/computational (functional assays, AlphaFold3) evidence.

Limitations and Knowledge Gaps

• Small evidence base: ~20 patients worldwide; phenotype frequencies derive from a single founding cohort (~15 evaluable individuals). Frequencies are precise-looking but statistically fragile.
• No epidemiology: no prevalence/incidence estimate; no Orphanet ORPHA or MeSH term.
• No prognostic biomarkers and no natural-history/longitudinal cohort data (e.g., adult final height distributions, scoliosis progression rates).
• Genotype–phenotype correlations are not yet established (whether hypomorphic missense vs null alleles predict severity).
• GH therapy efficacy is untested rigorously—used empirically with unproven benefit.
• TGF-β/FGF/Hedgehog contributions to the human phenotype are inferred; only the BMP arm is directly demonstrated for the disease.
• Cognitive-sparing mechanism (why SCUBE3 loss largely spares cognition despite CNS expression) is unexplained.

Proposed Follow-up Experiments / Actions

1. Establish an international patient registry to capture natural history: final adult height, scoliosis progression, cardiac and dental outcomes, and QoL (SF-36/PROMIS).
2. Genotype–phenotype study correlating residual SCUBE3 secretion/function (per-variant in-vitro assays) with clinical severity to build a variant-effect map on NM_152753.4.
3. Controlled evaluation of recombinant GH (or, mechanistically, growth-plate-directed BMP-pathway modulation) in a small cohort, given the local BMP defect rationale.
4. Conditional/tissue-specific Scube3 mouse models (chondrocyte-, neural-crest-, cardiac-specific) to dissect the phenotype branches and test BMP-augmentation rescue.
5. Deep phenotyping of the cardiac and ocular spectrum to refine "with or without cardiac anomalies" penetrance estimates.
6. Structural/biochemical work on how missense EGF-repeat disulfide disruptions impair secretion, to identify potentially rescuable (chaperone-amenable) alleles.
7. Formal ClinGen/ACMG variant curation and gene-disease validity classification to standardize diagnostic reporting.

Report compiled from 10 confirmed findings across 5 investigation iterations. Evidence sources: human clinical cohorts/case reports, mouse and zebrafish model organisms, in-vitro functional assays, and computational structural modeling.